Following the lead of lumpectomy for breast cancer, focal therapy for prostate cancer was introduced in order to limit morbidity while providing good cancer control. Focal therapy is now an established trend in prostate cancer management, but long-term data have not been available. This report presents results on 70 patients treated with focal cryoablation, followed for an average of 10 years.
Methods:
Between May 7, 1996, and December 28, 2005, seventy patients were treated with focal cryoablation. All patients were pre-staged using an additional prostate biopsy—either transrectal ultrasound (TRUS) biopsy or transperineal three-dimensional prostate mapping biopsy (3D-PMB). All patients were treated with focal cryoablation of the known tumor(s). Biochemical disease-free status was determined by the Phoenix criteria.
Results:
Disease-specific survival was 66/66 (100%). Overall biochemical disease-free survival (BDFS) was 62/70 (89%). BDFS results stratified according to the D'Amico criteria were: 8/9 (89%) high risk; 28/32 (88%) medium risk; and 26/29 (90%) low risk. There was no statistically significant difference between the risk levels. Of those patients staged by TRUS biopsy, 8 of 24 patients had a documented local recurrence (33%). Of those staged by (3D-PMB), 2 of 46 (4%) patients had a local recurrence. Nine out of ten retreated local recurrences (90%) remain BDF. Continence after the first treatment was 100% (no pads). Potency after the first treatment was 94%, including retreatments it was 74%.
Conclusions:
The long-term cancer control results of focal cryoablation appear superior in medium- and high-risk patients to radical whole gland treatments. Focal therapy is associated with extremely low morbidity. If confirmed and applied widely, focal cryoablation could result in a substantial decrease in prostate cancer related mortality while offering a better post treatment quality of life.
Get full access to this article
View all access options for this article.
References
1.
OnikG, NarayanP, VaughanD, DineenM, BrunelleR. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: A new approach to preserving potency. Urology, 2002; 60:109–114.
2.
BahnDK, SilvermanP, LeeFSr., BadalamentR, BahnED, RewcastleJC. Focal prostate cryoablation: Initial results show cancer control and potency preservation. J Endourol, 2006; 20:688–692.
3.
BahnD, de Castro AbreuAL, GillIS, HungAJ, SilvermanP, GrossME. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol, 2012; 62:55–63.
4.
de Castro AbreuAL, BahnD, LeslieS, et al.Salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy. BJU Int, 2013; 112:298–307.
5.
HaleZ, MiyakeM, PalaciosDA, RosserCJ. Focal cryosurgical ablation of the prostate: A single institute's perspective. BMC Urol, 2013; 13:2.
6.
AhmedHU, AryaM, CarrollPR, EmbertonM, editors. Focal therapy in prostate cancer. Chichester, West Sussex, UK: Wiley-Blackwell, 2012.
7.
van den BosW, MullerBG, AhmedH, et al.Focal therapy in prostate cancer: International multidisciplinary consensus on trial design. Eur Urol, 2014; 65:1084–1085.
8.
BostwickDG, WatersDJ, FarleyER, et al.Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology, 2007; 70:42–44.
9.
OnikG, MiessauM, BostwickDG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol, 2009; 27:4321–4326.
10.
BostwickD. Quality assurance in prostate biopsy sampling: A new pathologic paradigm for prostate cancer diagnosis. In: PolascikTJ. Imaging and focal therapy of early prostate cancer. New York: Humana Press, 2013.
11.
OnikGM, CohenJK, ReyesGD, RubinskyB, ChangZ, BaustJ. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer, 1993; 72:1291–1299.
12.
OnikG, NarayanP, BrunelleR, VaughnD, DineenM, BrownT. Saline injection into Denonvilliers's fascia during prostate cryosurgery. J Min Inv Therapy and Relat Tech, 2000; 6:423–427.
13.
RossJS, WangR, LongJB, GrossCP, MaX. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med, 2012; 172:1601–1603.
14.
[No authors listed]. Active surveillance for early-stage prostate cancer. Lancet, 2014; 383:188.
15.
DjavanB, SusaniM, BursaB, BasharkhahA, SimakR, MarbergerM. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol, 1999; 5:139–142.
16.
VillersA, McNealJE, FreihaFS, StameyTA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer, 1992; 70:2313–2318.
17.
NoguchiM, StameyTA, McNealJE, NolleyR. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary cancers. J Urol, 2003; 170:459–463.
18.
RukstalisDB, GoldknopfJL, CrowleyEM, GarciaFU. Prostate cryoablation: A scientific rationale for future modifications. Urology, 2002; 60:19–25.
19.
SinghPB, AneleC, DaltonE, et al.Prostate cancer tumour features on template prostate-mapping biopsies: Implications for focal therapy. Eur Urol, 2013. [Epub ahead of print]; DOI: 10.1016/j.eururo.2013.09.045.
20.
HolundB. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol, 1980; 14:29–35.
21.
GiesingM, DrieselG, MolitorD, SuchyB. Molecular phenotyping of circulating tumour cells in patients with prostate cancer: Prediction of distant metastases. BJU Int, 2012; 110:E1202–211.
22.
CrawfordED, WilsonSS, TorkkoKC, et al.Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJU Int, 2005; 96:999–1004.
23.
CrawfordED, RoveKO, BarqawiAB, et al.Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate, 2013; 73:778–787.
24.
BarqawiAB, RoveKO, GholizadehS, O'DonnellCI, KoulH, CrawfordED. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol, 2011; 186:80–85.
25.
TairaAV, MerrickGS, GalbreathRW, et al.Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis, 2010; 13:71–77.
26.
BittnerN, MerrickGS, ButlerWM, BennettA, GalbreathRW. Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy. J Urol, 2013; 190:509–514.
27.
TsivianM, AbernMR, QiP, PolascikTJ. Short-term functional outcomes and complications associated with transperineal template prostate mapping biopsy. Urology, 2013; 82:166–170.
28.
BarzellWE, MelamedMR. Appropriate patient selection in the focal treatment of prostate cancer: The role of transperineal 3-dimensional pathologic mapping of the prostate–a 4-year experience. Urology, 2007; 70:27–35.
29.
DelongchampsNB, BeuvonF, EissD, et al.Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis, 2011; 14:232–237.
30.
BratanF, NiafE, MelodelimaC, et al.Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: A prospective study. Eur Radiol, 2013; 23:2019–2029.
31.
Abd-AlazeezM, KirkhamA, AhmedHU, et al.Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: A paired validating cohort study using template prostate mapping biopsies as the reference standard. Prostate Cancer Prostatic Dis, 2014; 17:40–46.
32.
DonnellyBJ, SalikenJC, BrasherPM, et al.A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer, 2010; 116:323–330.
33.
GouldRS. Total cryosurgery of the prostate versus standard cryosurgery versus radical prostatectomy: Comparison of early results and the role of transurethral resection in cryosurgery. J Urol, 1999; 162:1653–1657.
34.
AlicikusZA, YamadaY, ZhangZ, et al.Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer, 2011; 117:1429–1437.
35.
BahnDK, LeeF, BadalamentR, KumarA, GreskiJ, ChernickM. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology, 2002; 60:3–11.
36.
GrimmP, BillietI, BostwickD, et al.Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int, 2012; 109:22–29.
37.
GinzburgS, NeversT, StaffI, et al.Prostate cancer biochemical recurrence rates after robotic-assisted laparoscopic radical prostatectomy. JSLS, 2012; 16:443–450.
38.
ValicentiRK, ThompsonIJr., AlbertsenP, et al.Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys, 2013; 86:822–828.
39.
ShulmanS, YantornoC, BronsonP. Cryo-immunology: A method of immunization to autologous tissue. Proc Soc Exp Biol Med, 1967; 124:658–661.
40.
AblinRJ, FontanaG. Cryoimmunotherapy: Continuing studies toward determining a rational approach for assessing the candidacy of the prostatic cancer patient for cryoimmunotherapy and postoperative responsiveness. An interim report. Cryobiology, 1980; 17:170–177.
41.
WaitzR, SolomonSB, PetreEN, et al.Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res, 2012; 72:430–439.
42.
KawanoM, NishidaH, NakamotoY, TsumuraH, TsuchiyaH. Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma. Clin Orthop Relat Res, 2010; 468:1373–1383.
43.
WardJF, DiblasioCJ, WilliamsC, GivenR, JonesJS. Cryoablation for locally advanced clinical stage T3 prostate cancer: A report from the Cryo-On-Line Database (COLD) Registry. BJU Int, 2013; 113:714–718.
44.
LambertEH, BolteK, MassonP, KatzAE. Focal cryosurgery: Encouraging health outcomes for unifocal prostate cancer. Urology, 2007; 69:1117–1120.
45.
FicarraV, NovaraG, RosenRC, et al.Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol, 2012; 62:405–417.
46.
FicarraV, NovaraG, AhleringTE, et al.Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol, 2012; 62:418–430.
47.
WardJF, JonesJS. Focal cryotherapy for localized prostate cancer a report from the national Cryo On-Line database. BJU Int, 2012; 109:1648–1654.
48.
TatsutaniK, RubinskyB, OnikG, DahiyaR, NarayanP. The effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urol, 1996; 48:441–447.
49.
GageAA, BaustJ. Mechanisms of tissue injury in cryosurgery. Cryobiology, 1988; 373:171–186.
50.
AhmedHU, FreemanA, KirkhamA, et al.Focal therapy for localized prostate cancer: A phase I/II trial. J Urol, 2011; 185:1246–1254.
51.
OtoA, SethiI, KarczmarG, et al.MR imaging-guided focal laser ablation for prostate cancer: Phase I trial. Radiology, 2013; 267:932–940.
52.
AzzouziAR, BarretE, MooreCM, et al.TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: Determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int, 2013; 112:766–774.
53.
OnikG, MikusP, RubinskyB. Irreversible electroporation: Implications for prostate ablation. Technol Cancer Res Treat, 2007; 6:295–300.
